Skip to content

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02869113
Enrollment
65
Registered
2016-08-16
Start date
2015-01-23
Completion date
2015-01-24
Last updated
2018-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sunscreen Agents

Brief summary

The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist.

Interventions

DRUGBAY98751 (Y65-110)

10 µL in one eye

DRUGBAY 98751 (Y65-102)

10 µL in one eye

DRUGBAY 98751 (Y65-106)

10 µL in one eye

10 µL in other eye

Sponsors

Bayer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female subjects, aged 18 to 60 years * No medical conditions of the eyes as determined by the subjects' medical history and confirmed by ophthalmologist * Subjects do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the day of and day after the study * Subject is willing to have the test materials instilled into the eyes and follow all protocol requirements * Subject is willing to refrain from using false eyelashes of any type or any topical prescription, OTC or cosmetic products on their eyes, eyelids, eyelashes or the peri-orbital areas of the face on the day of the study. * Subjects should refrain from use of make-up on testing day

Design outcomes

Primary

MeasureTime frame
Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject using a 5-category intensity scaleup to 24 hours
Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment scoreup to 24 hours
Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment scoreup to 24 hours
Post installation eye effects were assessed using a 5-category intensity scoreup to 24 hours

Secondary

MeasureTime frame
Number of adverse events as a measure of safety and tolerabilityat 24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026